2-((4-bromophenyl)(methoxy)methylene)malononitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((4-bromophenyl)(methoxy)methylene)malononitrile
• 英文别名: 2-((4-Bromophenyl)(methoxy)methylene)malononitrile；2-[(4-bromophenyl)-methoxymethylidene]propanedinitrile
• 化学式: C₁₁H₇BrN₂O
• 分子量: 263.093
• InChiKey: PYXJIIXBTXFWKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  15.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  56.81
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-((4-bromophenyl)(methoxy)methylene)malononitrile 在 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 3-(4-bromophenyl)-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  参考文献：
  名称：

  Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines

  摘要：

  Abnormal activation of B-cell receptor (BCR) signaling plays a key role in the development of lymphoid malignancies, and could be reverted by the simultaneous inhibition of Lyn, Fyn and Blk, three members of the Src family kinase (SFK).Fyn and Blk are also promising targets for the treatment of some forms of T-cell non-Hodgkin lymphoma which point to the druggability of SFKs for the treatment of these cancers. We recently identified Si308 as a potent Fyn inhibitor, while preliminary data showed that it might also inhibit Lyn and Blk. Here, molecular modelling studies were coupled with enzymatic assays to further investigate the effect of Si308 on Lyn and Blk. A small library of pyrazolo[3,4-d]pyrimidines structurally related to Si308 was synthesized and tested on human lymphoma cell lines. Compound 2h emerged as a new multitarget inhibitor of Lyn, Fyn and Blk endowed with remarkable antiproliferative effects on human B and T lymphoma cell lines. Its favorable ADME properties make the compound suitable for further developments. (C) 2019 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2019.07.048
• 作为产物：
  描述：

  4-溴苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.17h， 生成 2-((4-bromophenyl)(methoxy)methylene)malononitrile
  参考文献：
  名称：

  取代的吡唑类化合物及包含该化合物的组合物及其用途

  摘要：

  本发明提供了一种取代的吡唑类化合物及包含该化合物的组合物及其用途，所述的化合物如式(I)所示化合物或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂化合物。式(I)化合物可作为可逆的布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase,BTK)抑制剂，用于治疗与BTK相关的疾病，具有高选择性和良好的药代动力学特性。

  公开号：

  CN115611810A

文献信息

• [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：REDX PHARMA PLC

  公开号：WO2017103611A1

  公开（公告）日：2017-06-22

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说，该发明的化合物可用作布鲁顿氏酪氨酸激酶（BTK）的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：PHARMASCIENCE INC

  公开号：WO2013177668A1

  公开（公告）日：2013-12-05

  The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

  本发明涉及一种新型的蛋白激酶抑制剂家族。具体而言，本发明涉及Tec和Src蛋白激酶家族成员的抑制剂。
• PROTEIN KINASE INHIBITORS
  申请人：Pharmascience, Inc.

  公开号：US20150191473A1

  公开（公告）日：2015-07-09

  The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

  本发明涉及一种新型的蛋白激酶抑制剂家族。具体而言，本发明涉及Tec和Src蛋白激酶家族成员的抑制剂。
• [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE COMME INHIBITEURS DE BTK POUR LE TRAITEMENT DU CANCER
  申请人：REDX PHARMA PLC

  公开号：WO2017046604A1

  公开（公告）日：2017-03-23

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说，该发明的化合物可用作布鲁顿氏酪氨酸激酶（BTK）的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• [EN] COMPOUNDS USEFUL FOR INHIBITING RET KINASE<br/>[FR] COMPOSÉS UTILES POUR INHIBER LA KINASE RET
  申请人：LILLY CO ELI

  公开号：WO2021222017A1

  公开（公告）日：2021-11-04

  Provided herein are RET kinase inhibitors according to the formula (I): pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.

  本文提供了根据公式（I）的RET激酶抑制剂，其药学上可接受的盐，药物组合物以及它们在治疗可用RET激酶抑制剂治疗的疾病中的使用方法，包括与RET相关的疾病和疾病。A、R1、n、X1、X2、X3、X4和R2在规范中给出了它们的含义。